Adakveo Market Report 2026

Adakveo Market Overview

• The Adakveo market growth in the historic period has been driven by limited treatment options for sickle cell disease, high burden of vaso occlusive crises • Market expansion is supported by growth in sickle cell patient population, expansion of access programs • Growth Driver: Rising Prevalence Of Sickle Cell Disease Driving Growth Of The Adakveo Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the adakveo market include: • Hospitals (Segmentation By By End-Use) → Expected gain of $0.03 Billion • Ambulatory Care (Segmentation By By End-Use) → Expected gain of $0.01 Billion

What Is Covered Under Adakveo Market?

Adakveo refers to a prescription drug that prevents vaso-occlusive crises in patients with sickle cell disease. It works by targeting P-selectin to reduce blood cell clumping and inflammation. Adakveo is used to lower the number of painful vaso-occlusive crises in people with sickle cell disease. The main indications in the adakveo market are sickle cell disease (adults and pediatric patients) and vaso-occlusive crisis prevention. Sickle cell disease refers to a group of inherited blood disorders characterized by abnormal hemoglobin, known as hemoglobin S. The various routes of administration include intravenous injection, infusion therapy, and oral, and several distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies. The different end-users encompass hospitals, clinics, ambulatory care, and home care.

What Is The Adakveo Market Growth Forecast?

The growth in the forecast period can be attributed to growth in sickle cell patient population, expansion of access programs, increased focus on preventive therapies, rising orphan drug investments, improved clinical guidelines adoption. Major trends in the forecast period include rising use of targeted therapies in sickle cell disease, growing focus on vaso occlusive crisis prevention, increased adoption of p selectin inhibitors, expansion of disease modifying treatments, improved long term management of rare blood disorders.

What Are The Drivers Of The Adakveo Market?

The increasing prevalence of sickle cell disease is expected to propel the growth of the adakveo market going forward. Sickle cell disease (SCD) refers to a group of inherited blood disorders caused by the presence of abnormal hemoglobin, known as hemoglobin S, in red blood cells. The increasing prevalence of sickle cell disease can be attributed to factors such as higher birth rates in regions with endemic malaria, genetic inheritance patterns, and improved survival rates due to advances in medical care, which allow more individuals to live longer with the condition. Adakveo helps sickle cell disease patients by reducing the frequency of vaso-occlusive crises, which are painful episodes caused by the blockage of blood flow in small vessels, through its mechanism of action that selectively inhibits the adhesion of sickle cells to blood vessel walls, thereby improving blood flow and alleviating the symptoms of this debilitating condition. For instance, in July 2024, according to the Pennsylvania Bar Institute (PBI), a US-based organization, in 2021, approximately 7.74 million people had sickle cell disease (SCD). The number of newborns diagnosed annually is projected to increase from 275,000 in 2021 to over 400,000 by 2050. Therefore, the increasing prevalence of sickle cell disease is driving the adakveo industry. A rise in healthcare expenditure is expected to boost the growth of the adakveo market going forward. Healthcare expenditure is attributed to the financial investment made by governments, private insurers, and individuals in the healthcare system to improve and expand medical services. Healthcare expenditure supports Adakveo by enabling greater investment in innovative treatments for sickle cell disease, improving patient access to this targeted therapy, which helps reduce the burden of vaso-occlusive crises and enhances the quality of life for patients, especially in regions with advanced healthcare systems and adequate funding for specialty drugs. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, healthcare spending in the UK grew by 5.6% from 2022 to 2023, a significant increase compared to the 0.9% growth in 2022. In 2023, the UK's healthcare expenditure totaled approximately $317.63 billion (£292 billion). Thus, the rise in healthcare expenditure will drive the growth of the adakveo industry. The increasing focus on targeted therapies is expected to propel the growth of the adakveo market going forward. Targeted therapies are treatments that specifically target and inhibit molecular abnormalities in cancer or other diseases to improve treatment precision and minimize harm to healthy cells. The rising focus on targeted therapies is primarily driven by the advancements in precision medicine, which enables personalized, more effective treatments based on individual genetic profiles. Adakveo enhances targeted therapies by specifically binding to P-selectin, reducing vaso-occlusive crises in sickle cell patients. It improves treatment precision by addressing a key driver of inflammation and adhesion, leading to fewer pain episodes and better clinical outcomes. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved 6 gene therapy products in 2023, up from 5 approvals in 2022. Therefore, the increasing focus on targeted therapies is driving the growth of the adakveo industry.

How Will The Drivers Impact Growth In The Global Adakveo Market?

• Rising Global Burden of Sickle Cell Disease and VOC Hospitalizations (High) – During the forecast period, the rising global burden of sickle cell disease and vaso-occlusive crisis (VOC) hospitalizations is expected to become a key growth driver for the adakveo market by 2030. Increasing prevalence of sickle cell disease across both developed and emerging healthcare systems is creating stronger demand for therapies that reduce recurrent pain crises and hospitalization frequency. Healthcare providers are emphasizing early intervention approaches that improve long-term patient outcomes and lower disease-related complications. Growing awareness programs and improved diagnosis rates are further expanding treatment accessibility across high-burden populations. This evolving treatment landscape is reinforcing steady market expansion. • Growing Adoption of Targeted Biologic Therapies in Hematology (Medium) – During the forecast period, the growing adoption of targeted biologic therapies in hematology is expected to emerge as a major factor driving the expansion of the adakveo market by 2030. Healthcare systems are increasingly transitioning toward precision-focused biologic treatments that address disease mechanisms while improving patient management outcomes. Biologic innovations are encouraging broader incorporation of advanced therapies into hematology treatment pathways, particularly for chronic and high-burden blood disorders. Expanding physician familiarity with targeted biologics and improving specialty treatment infrastructure are further supporting therapeutic adoption. • Favorable Regulatory Support and Orphan Drug Incentives (Low) – During the forecast period, the favorable regulatory support and orphan drug incentives are expected to act as a key growth catalyst for the adakveo market by 2030. Regulatory agencies continue to strengthen support mechanisms for rare disease therapies through accelerated pathways, market exclusivity provisions, and development incentives. Pharmaceutical companies are increasingly prioritizing orphan disease biologics due to improved commercialization opportunities and streamlined approval environments. These initiatives are encouraging continued investment in specialized hematology therapeutics while supporting broader patient access to innovative treatment options.

How Will The Restraints Impact Growth In The Global Adakveo Market?

• High Treatment Cost and Limited Accessibility in Developing Regions (High) – During the forecast period, the high cost associated with biologic therapies such as Adakveo limits widespread adoption, particularly in low- and middle-income countries where sickle cell disease prevalence is high. Regular intravenous administration, hospital visits, and long-term therapy requirements increase the overall economic burden on patients and healthcare systems. Many developing countries lack sufficient reimbursement frameworks for expensive specialty biologics, restricting patient access. In regions with limited healthcare infrastructure, affordability challenges often force patients to rely on conventional low-cost therapies instead of advanced biologics. Budget constraints within public healthcare systems also reduce procurement and treatment availability. These financial barriers continue to hinder global market penetration. • Concerns Regarding Clinical Efficacy and Regulatory Setbacks (Medium) – During the forecast period, the one of the major restraints affecting the Adakveo market is uncertainty regarding long-term clinical efficacy following disappointing Phase III trial outcomes. The STAND study failed to demonstrate a significant reduction in vaso-occlusive crises compared with placebo, leading to regulatory concerns in Europe. As a result, the European Medicines Agency recommended revocation of the drug’s authorization, negatively impacting physician confidence and market perception. Such developments create hesitation among healthcare providers regarding continued prescribing practices. Negative clinical trial outcomes can also influence payer reimbursement decisions and slow adoption in additional markets. These regulatory setbacks remain a significant barrier to broader commercial growth • Competition from Emerging Gene Therapies and Novel Sickle Cell Disease Treatments (Low) – During the forecast period, the Adakveo market faces increasing restraint from the rapid development of innovative therapies for sickle cell disease, including gene-editing technologies, gene therapies, and next-generation targeted treatments. Several emerging therapies aim to provide long-term or potentially curative outcomes by addressing the underlying genetic causes of the disease rather than managing symptoms alone. As these advanced treatment options demonstrate promising clinical results and gain regulatory approvals, physicians and patients may increasingly favor them over chronic biologic therapies. In addition, growing investment in curative treatment approaches could shift healthcare spending and research focus away from existing therapies. This evolving competitive landscape may limit the long-term market growth potential of Adakveo.

Key Players In The Global Adakveo Market

Major companies operating in the adakveo market are Novartis AG

What Defines the Adakveo Market?

The adakveo market consists of sales of infusion sets, vials, injectable crizanlizumab, needles, and syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adakveo Market Report 2026?

The adakveo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adakveo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.